Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Bevacizumab (Primary) ; Iparomlimab/tuvonralimab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 11 Jun 2025 New trial record